Renal phosphate wasting due to tumor-induced osteomalacia: A frequently delayed diagnosis

Kidney International

Volumn 76, Issue 3, 2009, Pages 342-347

  Gore, M Odette ^a,b   Welch, Brian J ^a,b   Geng, Weidong ^a,b   Kabbani, Wareef ^b   Maalouf, Naim M ^a,b   Zerwekh, Joseph E ^a,b   Moe, Orson W ^a,b   Sakhaee, Khashayar ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; INDOMETACIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

ADULT; ANAMNESIS; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; BONE PAIN; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CASE REPORT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; KYPHOSIS; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL;

BIOPSY; DELAYED DIAGNOSIS; FEMALE; HUMANS; HYPOPHOSPHATEMIA; ILIUM; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; NOSE NEOPLASMS; OSTEOMALACIA;

EID: 67651092347     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.355     Document Type: Article

References (22)

1. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord 2001; 2: 175-186.
2. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000; 27: 333-338.
3. Schiavi SC, Moe OW. Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 2002; 11: 423-430.
4. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285: E1-E9.
5. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004; 65: 1-14.
6. Berndt TJ, Schiavi S, Kumar R. 'Phosphatonins' and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289: F1170-F1182.
7. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci 2001; 98: 6500-6505.
8. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semi Dial 2007; 20: 302-308.
9. Huang QL, Feig DS, Blackstein ME. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest 2000; 23: 263-267.
10. Savio RM, Gosnell JE, Posen S et al. Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 2004; 139: 218-222.
11. Walton RJ, Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975; 306: 309-310.
12. Dixon PH, Christie PT, Wooding C et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. J Clin Endocrinol Metab 1998; 83: 3615-3623.
13. Jan de Beur SM, Streeten EA, Civelek AC et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002; 359: 761-763.
14. Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 1999; 24: 130-131.
15. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89: 3979-3982.
16. van Boekel G, Ruinemans-Koerts J, Joosten F et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 2008; 158: 431-437.
17. Jan de Beur SM. Tumor-induced osteomalacia. JAMA 2005; 294: 1260-1267.
18. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalaciaassociated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 1-30.
19. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 2007; 357: 422-424.
20. Paglia F, Dionisi S, Minisola S. Octreotide for tumor-induced osteomalacia. N Engl J Med 2002; 346: 1748-1749.
21. Seufert J, Ebert K, Muller J et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001; 345: 1883-1888.
22. Baum M, Loleh S, Saini N et al. Correction of proximal tubule phosphate transport defect in Hyp mice in vivo and in vitrowith indomethacin. Proc Natl Acad Sci USA 2003; 100: 11098-11103.